Show simple item record

dc.contributor.authorAttard, G.
dc.contributor.authorBrown, L. C.
dc.contributor.authorClarke, Noel W
dc.contributor.authorParmar, M. K. B
dc.contributor.authorJames, N. D.
dc.date.accessioned2021-08-17T12:22:49Z
dc.date.available2021-08-17T12:22:49Z
dc.date.issued2021en
dc.identifier.citationAttard G, Brown LC, Clarke NW, Parmar MKB, James ND. Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. European Urology. 2021 Jul.en
dc.identifier.pmid34274134en
dc.identifier.doi10.1016/j.eururo.2021.06.023en
dc.identifier.urihttp://hdl.handle.net/10541/624468
dc.description.abstractNoneen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.eururo.2021.06.023en
dc.titleShould patients with high-risk localised or locally advanced prostate cancer receive abiraterone acetate in addition to androgen deprivation therapy? update on a planned analysis of the STAMPEDE Trialen
dc.typeOtheren
dc.contributor.departmentUniversity College London Cancer Institute, London, UK.en
dc.identifier.journalEuropean Urologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record